These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22668959)

  • 21. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).
    Eissa A; Krass I; Bajorek BV
    J Clin Pharm Ther; 2012 Dec; 37(6):620-9. PubMed ID: 22708668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
    Flint AC; Gupta R; Smith WS; Kamel H; Faigeles BS; Cullen SP; Rao VA; Bath PM; Wahlgren N; Ahmed N; Donnan GA;
    Int J Stroke; 2014 Aug; 9(6):705-10. PubMed ID: 25042855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous Thrombolysis for Acute Ischemic Stroke due to Cervical Internal Carotid Artery Occlusion.
    Yeo LL; Kong WY; Paliwal P; Teoh HL; Seet RC; Soon D; Rathakrishnan R; Ong V; Lee TH; Wong HF; Chan BP; Leow WK; Yuan C; Ting E; Gopinathan A; Tan BY; Sharma VK
    J Stroke Cerebrovasc Dis; 2016 Oct; 25(10):2423-9. PubMed ID: 27344361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
    Mori M; Naganuma M; Okada Y; Hasegawa Y; Shiokawa Y; Nakagawara J; Furui E; Kimura K; Yamagami H; Kario K; Okuda S; Koga M; Minematsu K; Toyoda K
    Cerebrovasc Dis; 2012; 34(2):140-6. PubMed ID: 22854333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Cologne stroke experience: safety and outcome in 450 patients treated with intravenous thrombolysis.
    Sobesky J; Frackowiak M; Zaro Weber O; Hahn M; Möller-Hartmann W; Rudolf J; Neveling M; Grond M; Schmulling S; Jacobs A; Heiss WD
    Cerebrovasc Dis; 2007; 24(1):56-65. PubMed ID: 17519545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of in-hospital mortality and the risk of symptomatic intracerebral hemorrhage after thrombolytic therapy with recombinant tissue plasminogen activator in acute ischemic stroke.
    Al-Khaled M; Matthis C; Eggers J
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):7-11. PubMed ID: 22578915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores.
    Wendt M; Tütüncü S; Fiebach JB; Scheitz JF; Audebert HJ; Nolte CH
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):550-3. PubMed ID: 23433783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset.
    Lorenzano S; Toni D;
    Int J Stroke; 2012 Apr; 7(3):250-7. PubMed ID: 22292526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy.
    Kim DJ; Kim DI; Kim SH; Lee KY; Heo JH; Han SW
    Neuroradiology; 2005 Aug; 47(8):616-21. PubMed ID: 15983773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low Alberta stroke program early computed tomography score within 3 hours of onset predicts subsequent symptomatic intracranial hemorrhage in patients treated with 0.6 mg/kg Alteplase.
    Hirano T; Sasaki M; Tomura N; Ito Y; Kobayashi S;
    J Stroke Cerebrovasc Dis; 2012 Nov; 21(8):898-902. PubMed ID: 21737309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenous thrombolysis for acute ischaemic stroke in a hospital without a specialised neuro-intensive care unit.
    Wiegand N; Lüthy R; Vogel B; Straumann E; Beynon C; Bertel O; Oelz O; Caspar CB
    Swiss Med Wkly; 2004 Jan; 134(1-2):14-7. PubMed ID: 14745662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Four-Year Experience of Symptomatic Intracranial Hemorrhage Following Intravenous Tissue Plasminogen Activator at a Comprehensive Stroke Center.
    Orlando A; Wagner JC; Fanale CV; Whaley M; McCarthy KL; Bar-Or D
    J Stroke Cerebrovasc Dis; 2016 Apr; 25(4):969-76. PubMed ID: 26856464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CT-based intravenous thrombolysis 3-4.5 hours after acute ischemic stroke in clinical practice.
    Sarikaya H; Fischer A; Valko PO; Weck A; Braun J; Georgiadis D; Baumgartner RW
    Neurol Res; 2011 Sep; 33(7):701-7. PubMed ID: 21756549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Symptomatic intracerebral hemorrhage after intravenous thrombolysis in Chinese patients: comparison of prediction models.
    Li M; Wang-Qin RQ; Wang YL; Liu LB; Pan YS; Liao XL; Wang YJ; Xu AD
    J Stroke Cerebrovasc Dis; 2015 Jun; 24(6):1235-43. PubMed ID: 25891755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of symptomatic intracranial haemorrhage in off-label thrombolysis: an analysis of the Safe Implementation of Treatments in Stroke registry.
    Mundiyanapurath S; Hees K; Ahmed N; Wahlgren N; Uhlmann L; Kieser M; Ringleb PA; Hacke W; Nagel S
    Eur J Neurol; 2018 Feb; 25(2):340-e11. PubMed ID: 29105904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of major neurological improvement after intravenous thrombolysis in acute ischemic stroke: a hospital-based study from south India.
    Boddu DB; Srinivasarao Bandaru VC; Reddy PG; Madhusudan M; Rukmini MK; Suryaprabha T; Jabeen SA; Suvarna A; Jayalakshmi SS; Meena AK; Borgohain R; Kaul S
    Neurol India; 2010; 58(3):403-6. PubMed ID: 20644268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ≥90 Years of Age.
    Arora R; Salamon E; Katz JM; Cox M; Saver JL; Bhatt DL; Fonarow GC; Peterson ED; Smith EE; Schwamm LH; Xian Y; Libman RB
    Stroke; 2016 Sep; 47(9):2347-54. PubMed ID: 27491734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial results.
    Schwamm LH; Wu O; Song SS; Latour LL; Ford AL; Hsia AW; Muzikansky A; Betensky RA; Yoo AJ; Lev MH; Boulouis G; Lauer A; Cougo P; Copen WA; Harris GJ; Warach S;
    Ann Neurol; 2018 May; 83(5):980-993. PubMed ID: 29689135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Off-label thrombolysis versus full adherence to the current European Alteplase license: impact on early clinical outcomes after acute ischemic stroke.
    Cappellari M; Moretto G; Micheletti N; Donato F; Tomelleri G; Gulli G; Carletti M; Squintani GM; Zanoni T; Ottaviani S; Romito S; Tommasi G; Musso AM; Deotto L; Gambina G; Zimatore DS; Bovi P
    J Thromb Thrombolysis; 2014 May; 37(4):549-56. PubMed ID: 23943338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.